Compare Core Scientific Inc (CORZ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs GeneDx Holdings Corp — how do they compare? Core Scientific Inc trades at $15.28 (market cap $4.94B), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: Core Scientific Inc is far larger — about 2.4× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and GeneDx Holdings Corp for 19 Days on average.
| CORZ | WGS | |
|---|---|---|
Market Cap | $4.94B | $2.02B |
Volume | 15,630,800 | 734,640 |
Sector | Technology | Health |
52-Week High | $29.16 | $167.51 |
52-Week Low | $13.57 | $34.51 |
Typical Hold Time | 20 Days | 19 Days |
Enterprise Value | $7.46B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.25, down 4.36% today amid a bearish technical trend. The stock shows weak fundamentals with a net loss of $288.62 million in 2025 and negative profit margins, though revenue is projected to grow to $440 million in 2026. Analyst sentiment remains strongly bullish with an 86% buy rating and a $32.75 consensus price target, but recent earnings misses and high cash burn pose significant risks.
The outlook is mixed: strong analyst support and insider buying suggest confidence in the AI data center strategy, but persistent losses, negative cash flow, and competitive pressures require careful monitoring. The stock's current price near support levels offers potential upside if execution improves, yet volatility and operational challenges present substantial downside risk.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
